Journal of Clinical Sleep Medicine最新文献

Study objectives: Determine whether preterm-born adolescents and adults have sleep-disordered breathing (SDB), as documented by abnormal overnight oximetry.

Methods: This single-center cross-sectional study prospectively enrolled adolescents and adults born moderately to extremely preterm (≤32 weeks gestation or <1500 grams birth weight) or full term to complete a study visit, STOP-Bang questionnaire, and overnight oximetry. Oxygen desaturation index (ODI) was compared in preterm versus term with Poisson regression models. Subgroup analyses in preterm participants evaluated associations of neonatal risk factors with ODI.

Results: Ninety-six preterm and 44 term participants completed study procedures. Preterm participants more often reported snoring (25% vs 9%; p=0.03) and excessive fatigue (62% vs 40%; p=0.02), and had higher body mass index, leading to higher STOP-Bang scores (2±1 vs 1±1; p<0.001). Preterm participants had 40% higher ODI (incidence rate ratio (IRR): 1.40; 95% CI [1.07,1.83]; p=0.02). However, after adjusting for classic risk factors for SDB including age and STOP-Bang score in a multivariable model, history of preterm birth did not predict additive risk for SDB. Among neonatal factors, a patent ductus arteriosus was associated with a higher ODI (IRR 1.99; 95% CI [1.37,2.91]; p<0.001).

Conclusions: Preterm-born adolescents and adults in this study have higher rates of snoring, daytime fatigue, and nocturnal desaturations compared to those term-born. However, the risk of elevated ODI is best attributed to obesity in this cohort and not the history of prematurity. Additionally, a history of a patent ductus arteriosus increased risk for SDB.

Study objectives: To examine the feasibility, adherence to therapy, and efficacy of hypoglossal nerve stimulation (HGNS) in adults with Down syndrome (DS) with obstructive sleep apnea.

Methods: Adults patients with DS who met criteria for hypoglossal nerve stimulation were prospectively enrolled. Objective adherence was extracted from a cloud-based compliance database. Pre-operative sleep studies were compared to follow-up testing performed no sooner than 3 months after device activation.

Results: Eleven adults with DS underwent implantation of HGNS between May 2021 and July 2024. Median age was 27 years old (interquartile range 26, 33), BMI 28.5kg/m² (26.5, 32.4), 27% were female, and had severe OSA (apnea-hypopnea index (AHI) 40/hr, (28.4, 42.9)). All patients were successfully implanted on an outpatient basis with no post-operative complications or readmissions and activated on schedule at 1 month after surgery. Adherence data show nightly usage longer than 4 hours was 100% and 96% of nights and a median of 9.2 and 8.5 hours/night in the first 30 and 90 days, respectively. Seven patients have undergone follow up testing and the median entire night AHI was reduced by 76%. All patients experienced a >50% decrease in AHI and to less than 15/hr. Median time spent below 88% improved from 2.0% (0.3,5.0) to 0.2% (0,0.6), and oxygenation nadir improved from 79.0% (75.5,85) to 88.0% (86.5,91).

Conclusions: In this small initial cohort, HGNS appears to be a safe, well-tolerated and efficacious treatment option for adults with DS with moderate-severe obstructive sleep apnea and positive airway pressure therapy intolerance.

Adherence to positive airway pressure (PAP) therapy is a challenge in patients with allergic rhinitis. We present a case of a 62-year-old male with OSA who had been struggling with PAP therapy for ten years. Intranasal fluticasone alone did not result in tolerance of PAP therapy. However, the combination of once- daily intranasal oxymetazoline with fluticasone led to significant improvement in tolerance and adherence to PAP therapy. While twice daily oxymetazoline alone has been associated with developing rhinitis medicamentosa, this side effect was not experienced by our patient. Some studies have shown that using intranasal oxymetazoline along with an intranasal steroid once daily for four weeks demonstrated improved effectiveness in relieving nasal symptoms with no development of rebound congestion or rhinitis medicamentosa. This strategy may be helpful in improving CPAP tolerance for patients with concurrent OSA and rhinitis, a potential area to explore in the future to improve PAP adherence.

The purpose of this investigation is to demonstrate a multimodality approach to the surgical management of obstructive sleep apnea. Hypoglossal nerve stimulator (HGNS) implantation has been a life-changing procedure for many patients with obstructive sleep apnea. When activated it produces tongue protrusion via electrical stimulation of the hypoglossal nerve. This advances the lingual tonsil, making the pharynx diameter greater. Unfortunately, for some patients the electrical stimulation required is too high and awakens the patient. In such cases the patient's fragmented sleep is not improved with the hypoglossal nerve stimulator. Here we present a case where hypoglossal nerve stimulator and CO₂ laser lingual tonsil reduction are used in conjunction to reduce the hypoglossal nerve stimulator setting required for airway patency, thereby allowing the patient to sleep through the night. For those patients who are unable to tolerate hypoglossal nerve stimulator settings, a combined approach with lingual tonsil reduction may be an alternative.

Citation: Fontenot A, Liu SYC, Dewan K. CO₂ laser lingual tonsil reduction as a treatment for tongue discomfort during hypoglossal nerve stimulation: a case report. J Clin Sleep Med. 2024;20(11):1857-1861.

Study objectives: There is limited knowledge regarding the progression or consistency of symptoms in obstructive sleep apnea (OSA) over time. Our objective was to examine the changes in symptom subtypes and identify predictors over a span of 5 years.

Methods: Data of 2,643 participants of the Sleep Heart Health Study with complete baseline and 5-year follow-up visits were analyzed. Latent class analysis on 14 symptoms at baseline and follow-up determined symptom subtypes. Individuals without OSA (apnea-hypopnea index < 5) were incorporated as a known class at each time point. Multinomial logistic regression assessed the effect of age, sex, body mass index, and apnea-hypopnea index on specific class transitions.

Results: The sample consisted of 1,408 females (53.8%) and mean (standard deviation) age 62.4 (10.5) years. We identified 4 OSA symptom subtypes at both baseline and follow-up visits: minimally symptomatic, disturbed sleep, moderately sleepy, and excessively sleepy. Nearly half (44.2%) of the sample transitioned to a different subtype; transitions to moderately sleepy were the most common (77% of all transitions). A 5-year older age was associated with a 50% increase in odds to transit from excessively sleepy to moderately sleepy (odds ratio [95% confidence interval]: 1.52 [1.17, 1.97]). Females had 1.97 times higher odds (95% confidence interval: 1.21, 3.18) to transition from moderately sleepy to minimal symptoms. A 5-unit increase in body mass index was associated with 2.39 greater odds (95% confidence interval: 1.30, 4.40) to transition from minimal symptoms to excessively sleepy. Changes in apnea-hypopnea index did not significantly predict any transitions.

Conclusions: The symptoms of OSA may fluctuate or remain stable over time. Knowledge of symptom progression in OSA may support clinicians with treatment decisions.

Citation: Morris JL, Scott PW, Magalang U, et al. Symptom subtype progression in obstructive sleep apnea over 5 years. J Clin Sleep Med. 2024;20(11):1773-1783.

Study objectives: Postoperative respiratory adverse events (PRAE) occurred more frequently in children having adenotonsillectomy than the general surgical population, and can require escalation of care. This study aims to assess the usefulness of postinduction fentanyl-test to predict PRAE in children with obstructive sleep apnea after adenotonsillectomy.

Methods: Two hundred and forty patients with obstructive sleep apnea undergoing adenotonsillectomy were included in this study. The oxygen saturation during sleep was monitored the night before adenotonsillectomy. Fentanyl-test was conducted under spontaneous breath after anesthesia induction with sevoflurane. Fentanyl-induced reduction in respiratory rate (FRR) was defined as the percentage of reduction in respiratory rate after 1 mcg/kg fentanyl administration. PRAE in the postanesthesia care unit included both respiratory complications and medical interventions. Receiver operating characteristic analysis was used to assess the usefulness of fentanyl-test in predicting PRAE.

Results: Of the 240 children undergoing elective adenotonsillectomy, 38 children (16%) experienced PRAE in postanesthesia care unit. The areas under receiver operating characteristic curve for FRR and nadir pulse oxygen saturation were 0.756 and 0.692, respectively. FRR greater than 53% best predicted PRAE in postanesthesia care unit, with a sensitivity of 68% and a specificity of 72%. Patients with FRR > 53% exhibited a significantly longer duration of desaturation requiring supplementary oxygen than those with FRR ≦ 53% (P < .001).

Conclusions: We suggest that postinduction fentanyl-test is a feasible evaluation for children undergoing adenotonsillectomy to predict early PRAE, especially for those who have not undergone polysomnography.

Clinical trial registration: Registry: ClinicalTrials.gov; Name: Effects of Individualized Opioid Analgesia Versus Conventional Opioid Analgesia After Adenotonsillectomy in Children; URL: https://clinicaltrials.gov/study/NCT04527393; Identifier: NCT04527393.

Citation: Liu H-E, He L. The performance of a post-induction fentanyl-test in predicting postoperative respiratory adverse events in children after adenotonsillectomy. J Clin Sleep Med. 2024;20(11):1749-1754.

Study objectives: The current study aimed to examine clinically relevant psychiatric and sociodemographic predictors of insomnia treatment outcomes in pediatric patients clinically referred for insomnia.

Methods: Pediatric patients (n = 1,428; ages 1.5-18 years) presenting for insomnia evaluation in a medical/sleep center-based behavioral sleep clinic were followed for treatment as clinically indicated. According to patient age, parents/patients completed validated measures of insomnia severity, psychiatric symptoms, and sociodemographic measures. Patients were also categorized by treatment outcome status (ie, not recommended to follow-up after initial evaluation and treatment session, successful treatment completion, lost to follow-up after initial evaluation and treatment session, and early termination) according to the clinically indicated treatment recommended and dose of treatment received.

Results: Youth had elevated scores on psychiatric screening indexes and affective problems were highest for all age groups. Other comorbid sleep disorders were present in nearly 25% of patients with insomnia and use of sleep aids (melatonin or hypnotics) was commonplace. Baseline insomnia severity significantly predicted sleep treatment trajectories and posttreatment insomnia severity with large effects for all age groups. Other clinically relevant predictors of insomnia treatment outcomes included medication use and externalizing mental health concerns in younger patients and internalizing mental health concerns and chronological age in older patients. Lack of treatment follow-up and premature treatment termination was observed for patients with the worst insomnia symptoms at time of initial evaluation.

Conclusions: Pediatric health providers delivering insomnia treatment should take a developmentally sensitive approach that is proactive with regards to managing treatment barriers that are likely influenced by severity of insomnia and comorbid mental health concerns.

Citation: Van Dyk TR, Simmons DM, Durracio K, Becker SP, Byars KC. The role of psychiatric symptoms, sociodemographic factors, and baseline sleep variables on pediatric insomnia treatment outcomes in a clinically referred population. J Clin Sleep Med. 2024;20(11):1727-1738.